Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

Leukemia

Volumn 27, Issue 10, 2013, Pages 1953-1958

  Barbui, T ^a   Thiele, J ^b   Vannucchi, A M ^c   Tefferi, A ^d  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

diagnostic problems; early prefibrotic primary myelofibrosis; essential thrombocythemia; myeloproliferative neoplasm; WHO classification

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA;

ALLELE; CODON; EARLY PREFIBROTIC PRIMARY MYELOFIBROSIS; EVENT FREE SURVIVAL; EXON; HEMATOLOGIST; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MOLECULAR GENETICS; MYELOID METAPLASIA; OSSIFICATION; OVERALL SURVIVAL; PATHOLOGIST; PRIORITY JOURNAL; REVIEW; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION;

EID: 84885606352     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.74     Document Type: Review

References (49)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
2. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
3. Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol 2007; 14: 115-122.
4. Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol 2008; 39: 795-810.
5. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
6. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008; 112: 231-239.
7. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-375.
8. Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2011; 117: 1472-1482.
9. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009; 4: 33-40.
10. Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20: 633-644.
11. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-A clinicopathological study on 272 patients. Histol Histopathol 2003; 18: 93-102.
12. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111: 60-70.
13. Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010; 56: 758-767.
14. Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European bone marrow working group trial on reproducibility of WHO criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012; 97: 360-365.
15. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
16. Thiele J, Kvasnicka HM, Mü llauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117: 5710-5718.
17. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
18. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
19. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders: incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993; 189: 121-132.
20. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998; 11: 721-749.
21. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002; 70: 283-291.
22. Kreft A, Bü che G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005; 113: 137-143.
23. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study of 1,104 patients. J Clin Oncol 2011; 29: 3179-3184.
24. Lones MA, Auperin A, Raphael M, McCarthy K, Perkins SL, MacLennan KA et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American lymphoma classification. Ann Oncol 2000; 11: 47-51.
25. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-hodgkin's lymphoma classification project. Ann Oncol 2002; 13: 140-149.
26. Koopmans SM, Bot FJ, Lam KH, van Marion AM, de Raeve H, Hebeda KM. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathos 2011; 136: 618-624.
27. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004; 89: 911-919.
28. Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006; 47: 1774-1781.
29. Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111: 1862-1865.
30. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andréasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 2011; 86: 148-15.
31. Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS et al. The European Consensus on grading of bone marrow fibrosid allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012; 25: 1193-1202.
32. Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PloS ONE 2012; 7: e35631.
33. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
34. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-A clinicopathologoical study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006; 85: 226-232.
35. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006; 32: 362-371.
36. Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Björkholm M, Löfvenberg E et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up. Hematology 2013; 18: 8-13.
37. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET Study-A randomized controlled trial. Blood 2013; 121: 1720-1728.
38. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117: 5857-5859.
39. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007; 109: 4105.
40. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112: 3135-3137.
41. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645-1651.
42. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al. Development and validation of an International Prognostic Score of thrombosis in WHOEssential Thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128-5133.
43. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mü llauer L et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis. Am J Hematol 2012; 87: 669-6672.
44. Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ et al. Correlation of blood counts with vascular complications in essential thro-mbocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120: 1409-1411.
45. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-719.
46. Harrison C, Barbui T. Aspirin in low-risk essential thrombocythemia, not so simple after all? Leuk Res 2011; 35: 286-289.
47. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009; 37: e1187.
48. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108: 3128-3134.
49. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.